Work

Abstract PS4-11-01: Medicare Part B Drug Cost Burden of Pembrolizumab Based Triple Negative and Dual HER2 Triple Positive Regimens for Early Breast Cancer at 2025 Q3 Payment Rates

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps4-11-01

Authors: P. Jain, V. Majmundar, C. Bhanushali, N. Ganatra, M. Patel, R. Patel, A. Kothari, K. Patel, T. Naqvi

Institutions: University of Miami, Saint Vincent Hospital, Smt. N.H.L. Municipal Medical College

Language: English

Topic: Economic and Financial Impacts of Cancer

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129640339

Cites:

Cited by:

Related to: